

PE/Fire™ 810 anti-human CD197 (CCR7)

Catalog # / Size: 2366345 / 25 tests

Clone: G043H7

Isotype: Mouse IgG2a, κ


Immunogen: CCR7-transfected cells

Reactivity: Human, Non-human primate, Other

Preparation: The antibody was purified by affinity chromatography and conjugated with PE/Fire™ 810 under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with anti-human CD3 FITC and anti-human CD197 (CCR7) (clone G043H7) PE/Fire™ 810 (left) or stained with anti-human CD3 FITC only (right).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PE/Fire™ 810 has a maximum excitation of 488/561 nm and a maximum emission of 810 nm.

Description: CCR7, also known as CD197, is a chemokine receptor that binds CCL19 and CCL21. CCR7 and its ligands link innate and adaptive immunity by affecting interactions between T cells and dendritic cells and their downstream effect. Naïve T cells enter the lymph node through high endothelial venules, which express CCL21. Dendritic cells and macrophages enter the lymph node through afferent lymphatics. The encounter of T cells and dendritic cells in the T cell zone is CCR7-dependent. In addition, during immunological surveillance, B cells recirculate between B-cell-rich compartments (follicles or B cell zones) in secondary lymphoid organs, surveying for antigen. After antigen binding, B cells move to the boundary of B and T zones to interact with T-helper cells; this B cell migration is directed by CCR7 and its ligands. CCR7-positive cancer cell expression has been associated with lymph node metastasis.

Antigen
References:

1. Yanagihara S, *et al.* 1998. *J. Immunol.* 161:3096.
2. Charo IF, *et al.* 2006. *N. Engl. J. Med.* 354:610.
3. Reif K, *et al.* 2002. *Nature* 416:94.
4. Nakata B, *et al.* 2008. *Oncology* 74:69.
5. Brodie T. *et al.* 2013. *Cytometry A.* 6: 530-2. [PubMed](#)
6. Graves A.J. *et al.* 2014. *Cytometry A.* 7: 576-9 [PubMed](#)
7. Moncunill G. *et al.* 2014. *Cytometry A.* 12: 995-8 [PubMed](#)